Etoposide

Catalog No.S1225 Synonyms: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 280 In stock
USD 690 In stock
USD 990 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly M1zVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3OTWM2OD1yLkGy5qCKyrIkgJmwMlAyKM7:TR?= MXyyOVk3ODJ6Mh?=
KellyCis83 MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fWNWlEPTB;MD6xOwKBkcLz4pEJNE4xOiEQvF2= MkjGNlU6PjB{OEK=
SK-N-AS MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TNe2lEPTB;MD6yOQKBkcLz4pEJNE4xOyEQvF2= MnztNlU6PjB{OEK=
SK-N-ASCis24 NIDzT5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwNUhihKnDueLCiUCuNVEh|ryP MofWNlU6PjB{OEK=
U87 NHqw[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDpNE02OCEQvF2= MUC0PEBp NH36OZJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4hq[2hiY3HuJIJmKGWwaHHuZ4VlKGK7IIPpcIljcW6rbh?= MUOyOVc2ODJ5Mx?=
HCT116 M17Sd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDIdWcxNjVvMj61JO69VQ>? NI\YOpQ1QMLiaNMg NFPtdJZKSzVyPUGuO|PDqMLzwrCwMlIyyqEQvF2= M4K1UFI2PzR4N{[z
HT-29 NF;QVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHqzPFUxNjVvMj61JO69VQ>? NH\rOVM1QMLiaNMg MVzJR|UxRTdwMtMgxtHDqDFwMEVCpO69VQ>? NWXEe3N[OjV5NE[3OlM>
Caco2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVmwMlUuOi53IN88US=> NIO3Zm01QMLiaNMg MXPJR|UxRTdwMkdCpOKyyqBzLk[4xsDPxE1? NWHScZVwOjV5NE[3OlM>
COLO 205 NIHqXYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[wW4plOC53LUKuOUDPxE1? MVm0POKhcMLi MU\JR|UxRTFwNkJCpOKyyqByLkCyxsDPxE1? NX71eVBEOjV5NE[3OlM>
SW480 NEXNR4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH3[JoxNjVvMj61JO69VQ>? NX[5eHNzPDkEoHlCpC=> NXP4O|VFUUN3ME20MlkzyqEEsdMgNE4{O8LizszN MYKyOVc1Pjd4Mx?=
HEK293T MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzFdFlEOS13IN88US=> MnvDOFjDqGkEoB?= NVPjVIFOUUN3ME2yMlQzyqEEsdMgNE4xPcLizszN Ml7HNlU4PDZ5NkO=
Hep3B  M{PQZ2Z2dmO2aX;uJGF{e2G7 NYnWdZJXOTBizszN Mnm4OFjDqGkEoB?= MnrUdoVlfWOnczD0bIUh\W6qYX7jbY5oKGWoZnXjeEBw\iCETWCtOi=> Mn;nNlU3OzN3NkS=
Hep3B  M3rnTWZ2dmO2aX;uJGF{e2G7 NVrydYpyOC5zLUGwJO69VQ>? MkC5NlQhcA>? NGHDdoZ{fXCycnXzd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGincHPp[IlvKG2UTlG= NHjmcnczPTZ|M{W2OC=>
HEK293 NX3sS3JqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPsNHZOUUN3ME23MlE1yqEEsdMgNE4{PsLizszN NIXxfIIzPTZyM{GyNi=>
DU145 M2\V[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\QTWM2OD1{LkK4xsDDucLiMD6wOOKh|ryP MV6yOVYxOzF{Mh?=
HCT15 M4S5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmGxTWM2OD1yLkixxsDDucLiMD6wNeKh|ryP NYXye5lzOjV4MEOxNlI>
T47D NVX0UnR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYryXlF1UUN3ME2zMlE5yqEEsdMgNE4yOcLizszN MnzyNlU3ODNzMkK=
SMMC-7721 M3u3fGZ2dmO2aX;uJGF{e2G7 NYXD[nA4PDBizszN M3HmPVQ5KGh? NGjkVnBFVVOR NGXNWGNqdmS3Y3XzJO6{UDKDWDDmc4NqKG[xcn3heIlwdg>? M{\iWVI2PTR2M{[x
MDA-MB-231 NGjFR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjZO|LDqGh? MUnJR|UxRTJzLkNCpOKyyqB2LkNCpO69VQ>? MkTWNlU1QDZ{MUm=
MCF-7 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXe3NuKhcA>? NUDKVZl2UUN3ME2xNE46yqEEsdMgNk4yyqEQvF2= MVSyOVQ5PjJzOR?=
Jurkat NXnx[ZBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7oO|LDqGh? MXHJR|UxRTFwMtMgxtHDqDFwNdMg{txO NUjRenBGOjV2OE[yNVk>
HeLa NVnjN5NNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHtO|LDqGh? MYTJR|UxRTNwOdMgxtHDqDJwM9Mg{txO M17xV|I2PDh4MkG5
MCF7  MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;i[|UuOTByIN88US=> NEOxWGo4KGR? NWL1UVh1cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NX;0NopPOjV2N{K2NVk>
K562 NEK5WW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjsO|LDqGh? M1XmUGlEPTB;MD6yPeKh|ryP NGKydmIzPTJ6Mk[1Ny=>
K/VP.5 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr3PXE2PzMEoHi= NGfSeItKSzVyPUSuPeKh|ryP M2LHcVI2Ojh{NkWz
SH-EP  M4jsT2Z2dmO2aX;uJGF{e2G7 Mn7tNlDDqM7:Zz;tcC=> NF3rVY0zPMLiaB?= NX7WXpZGcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGWwZH;n[Y5wfXNiRFXQVC=> MU[yOVI3OTl6MR?=
SCC25 NH22fo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlm3NlTDqGh? M{nuWWlEPTB;NEOuN:KhyrIEoEGuNVLDqM7:TR?= NWWzeVYyOjV{MkC3Nlk>
CAL27 MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWiyOOKhcA>? MXjJR|UxRTV{LkJCpOKyyqBzLkC5xsDPxE1? NEDidW4zPTJ{MEeyPS=>
FaDu M33w[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M322W|I1yqCq MWfJR|UxRTJ3Lki5xsDDucLiMT6xN:Kh|ryP MmezNlUzOjB5Mkm=
SCC25 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUW0POKhcA>? NFPh[4RKSzVyPUKwMlg3yqEEsdMgNU4xP8LizszN MUmyOVIzODd{OR?=
CAL27 NV;1cWhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\LbHk1QMLiaB?= NV7WeW5{UUN3ME2xPE4zPMLiwsJCpFEvOTYEoN88US=> M4XDZlI2OjJyN{K5
FaDu MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLLXoo5PDkEoHi= MlnDTWM2OD14LkSzxsDDucLiMT6xN:Kh|ryP MWGyOVIzODd{OR?=
SCC25 NGPS[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnW4O|LDqGh? NYD2NVlOUUN3ME24MlQyyqEEsdMgNU4yOcLizszN NEHBe5MzPTJ{MEeyPS=>
CAL27 M2nRbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFqyW2M4OsLiaB?= MlrBTWM2OD12LkK3xsDDucLiMT6xOOKh|ryP M2\iZlI2OjJyN{K5
FaDu M3q0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFS5[ZM4OsLiaB?= Ml\oTWM2OD13LkCyxsDDucLiMT6xOeKh|ryP M{L1Z|I2OjJyN{K5
MCF-7 NVK1N2I4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[0POKhcMLi MV;EUXNQ M4TDXGlEPTB;Nz6yxsDDucLiMD64xsDPxE1? M1vUXVI2OjF4M{e4
T-47D MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrWNYg1QMLiaNMg NGP6SI1FVVOR M1HtfGlEPTB;Nz63xsDDucLiMD63xsDPxE1? M13nTVI2OjF4M{e4
MDA-MB-231 NGi5fFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzTOFjDqGkEoB?= NVfRcI81TE2VTx?= M{P2e2lEPTB;MUKuPOKhyrIEoEGuNOKh|ryP NGOwV3kzPTJzNkO3PC=>
DU145 NGL6b|RCeG:ydH;zbZMhSXO|YYm= Mnv4NVAuOTByIN88US=> Mn7ZPEBp Mmi0SG1UVw>? MmDCbY5lfWOnczDj[YxtKGSnYYToJJNq\26rZnnjZY51dHliaX6gZUB3\XK7IHzve{Bkd26lZX70doF1cW:w MmfMNlUyPDl4OEG=
DU145 stem-like NIiwPXJCeG:ydH;zbZMhSXO|YYm= NEj3fWEyOC1zMECg{txO M{DaclghcA>? NHP3fZpFVVOR MkDibY5lfWOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NXHoUZFKOjVzNEm2PFE>
DU145 NVmzVpY6TnWwY4Tpc44hSXO|YYm= MnvrNVAuOTByIN88US=> M1;kZ|IhcA>? MkG5SG1UVw>? NE[3WGNqdmO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iYX7kJIRm[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYOyOVE1QTZ6MR?=
DU145 stem-like MXzGeY5kfGmxbjDBd5NigQ>? NXizUWtqOTBvMUCwJO69VQ>? MUOyJIg> NV3xV4tETE2VTx?= MmfMbY5kemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGGwZDDk[YNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MXGyOVE1QTZ6MR?=
UW228-3 NFLUSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXyyNJU2OC5yMT2zNFAh|ryP MYq0PEBp NYrYb4toTE2VTx?= NGTld4tKSzVyPUCuPVnDqM7:TR?= MnXNNlUyOTlzOEW=
NSCs MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXOPGFqOC5yMT2zNFAh|ryP MVm0PEBp NFnDeG1FVVOR MnuxTWM2OD1yLkOtN:Kh|ryP M2GwRVI2OTF7MUi1
MKL-1  MUPGeY5kfGmxbjDBd5NigQ>? NIrSUlEyOC1zMECwJI5O NH;HbnQ1KGR? MWHpcoR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZiTVjDMWkh\XiycnXzd4lwdg>? MXiyOVEyPjd3NB?=
MCF7 EV NIXCV4FHfW6ldHnvckBCe3OjeR?= M1X2bFExNTFyMDFOwG0> NWnuNlJOOuLCiXi= NE\acVBqdmS3Y3XzJJBzd2S3Y4Tpc44hd2cEoN8zTFJCYA>? NGG5O48zPTB6OEKwNy=>
MCF 7BMI1 NGqxPXRHfW6ldHnvckBCe3OjeR?= NXHzbHR1OTBvMUCwJO69VQ>? NXnu[IZ3OuLCiXi= MojGbY5lfWOnczDwdo9lfWO2aX;uJI9nyqEQs1iyRXg> NXnGbVMxOjVyOEiyNFM>
MCF7 EV M2XPd2Z2dmO2aX;uJGF{e2G7 NITBRnMyOC1zMECg{txO NEnYVY0z6oDLaB?= M{jLWWVVV1BiaX7keYNmeyCDVF2gZYN1cX[jdHnvci=> MViyOVA5QDJyMx?=
MCF7 BMI1 Mlm4SpVv[3Srb36gRZN{[Xl? NYH0OHZiOTBvMUCwJO69VQ>? NIr4VmUz6oDLaB?= MUfFWG9RKGmwZIXj[ZMhSVSPIHHjeIl3[XSrb36= M1vTfFI2ODh6MkCz
HepG2 MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVH1WZhCTE2VT9Mg Mlq1TWM2OD1|MD6xOuKhyrIEoECuOVDDqM7:TR?= NV\SbmtJOjVyN{izNVE>
MOLT-3 M1rITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnEUXNQyqB? MX3JR|UxRTBwMEWxxsDDucLiMD6wNFLDqM7:TR?= MV[yOVA4QDNzMR?=
HT1080 NFXGbYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfKT3YyNTFyMDFOwG0> NXPUSIRZPC9{ND:0PEBp NX\EOohSTE2VT9Mg M1y5Z4lv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7IHnuJIEhfmW{eTDsc5ch[2:wY3XueJJifGmxbh?= NUTWeVAzOjVyN{iwOlQ>
HT1080 NIjCOIxHfW6ldHnvckBCe3OjeR?= MkDQNE4xODBzLUGwNEDPxE1? NHq5OnEyNTJ2IHi= NYn3PFQ2TE2VT9Mg MV;pcoR2[2W|IICtdFU{MHOnckG1LUBqdiCkb4ToJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? NIPZb5ozPTB5OEC2OC=>
HT1080 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLxNE4xODBzLUGwNEDPxE1? MUCyOEBp NYjObVNCTE2VT9Mg MkTlZ4F2e2W|IHHuJIlv[3KnYYPlJIlvKHSqZTDueY1j\XJib3[gZ4VtdHNiaX6gS|IwVSxid3jpcIUh\GWlcnXhd4lv\yCVIHHu[EBIOSCyaHHz[UBk\Wyucx?= Ml:xNlUxPzhyNkS=
HD-MY-Z NXTwcllPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\UbVI1NzR6L{eyJIg> MXHJR|Ux97zgMUCwJO69VQ>? NGT0b5ozPTB2OEKzOi=>
DOHH-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnkW5NwOjRiaB?= M4rKb2lEPTExvK6xNFAh|ryP NH[1d4czPTB2OEKzOi=>
DOHH-2 M{jDNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml60OFghcA>? NIrMTINKSzVyPUG5MlnDqM7:TR?= NHfrNGkzPTB2OEKzOi=>
DOHH-2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jIO|czKGh? NGHEZYhKSzVyPUZCpO69VQ>? NHK4TG4zPTB2OEKzOi=>
REH NInFdnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWmyOEBp M3HyOmlEPTB;MD6wNlfDqM7:TR?= NF\xe|kzPTB2OEKzOi=>
REH M1jkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPJO2I1QCCq NWDqU4tnUUN3ME2wMlAyPMLizszN M4XJVFI2ODR6MkO2
REH MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDnbIhtPzJiaB?= NIDGVmZKSzVyPUCuNFE2yqEQvF2= MoD1NlUxPDh{M{[=
HH NEHWd2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn3dlZWOjRiaB?= NXzRSGFiUUN3ME2xNFQvP8LizszN NVLZ[YlbOjVyNEiyN|Y>
HH MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XtbVQ5KGh? MX7JR|UxRTR6LkdCpO69VQ>? MXGyOVA1QDJ|Nh?=
HH NWW3V3JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVO3NkBp MlLHTWM2OD1zND63xsDPxE1? NW[wW3JGOjVyNEiyN|Y>
HuT-78 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rFeVI1KGh? M3:2RWlEPTB;OT6zxsDPxE1? MWeyOVA1QDJ|Nh?=
HuT-78 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fCfVQ5KGh? Mm\5TWM2OD12LkRCpO69VQ>? NEXiOm4zPTB2OEKzOi=>
HuT-78 M{W4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXmO|IhcA>? M{OwZWlEPTB;ND6yxsDPxE1? NIPoWVEzPTB2OEKzOi=>
OPM-2 Mlu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrjWlgzPCCq MkLwTWM2OD1{ND6xxsDPxE1? NWrjcGdXOjVyNEiyN|Y>
OPM-2 NV6xcWhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;FOFghcA>? M3HVc2lEPTB;NNMg{txO NFPjSG8zPTB2OEKzOi=>
OPM-2 NF25WJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X6eVczKGh? MVTJR|UxRTFwM9Mg{txO MlTENlUxPDh{M{[=
RPMI-8226 NW\1N29MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXiNlQhcA>? MljsTWM2OD1zME[uOuKh|ryP MVuyOVA1QDJ|Nh?=
RPMI-8226 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYe0PEBp MWHJR|UxRTlzLkJCpO69VQ>? M1LGUlI2ODR6MkO2
RPMI-8226 NWjmNWcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TwS|czKGh? MXTJR|UxRTF2LkpCpO69VQ>? M3TyVFI2ODR6MkO2
U-266 MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLLNlQhcA>? NFzkXmJKSzVyPUi2MlLDqM7:TR?= MXeyOVA1QDJ|Nh?=
U-266 M2XsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorEOFghcA>? MXrJR|UxRTZ6LkVCpO69VQ>? MoTkNlUxPDh{M{[=
U-266 M{LQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDHc2hyPzJiaB?= NY\6PHc{UUN3ME2yO{41yqEQvF2= NWLGOpBzOjVyNEiyN|Y>
Kelly MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvuVZppOC1zMDFOwG0> NHLSW4s4OsLiaB?= MUnJR|UxRTFwNUG4xsDPxE1? M{S3RVI2ODB6OUCw
SH-SY5Y  M3PyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWwMVExKM7:TR?= MWq3NuKhcA>? MoDMTWM2OD1yLke1OOKh|ryPwrC= M2q5dFI2ODB6OUCw
SK-N-AS NXXxRZV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP5[4MxNTFyIN88US=> M1L1TFczyqCq M{PsfWlEPTB;MT63NVLDqM7:TdMg MnHCNlUxODh7MEC=
SK-N-DZ MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\5SnFGOC1zMDFOwG0> MWe3NuKhcA>? MUjJR|UxRTVwNEi1xsDPxE1? MlT2NlUxODh7MEC=
HepG2 MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jvOVQ5yqCq MWLEUXNQyqB? MXfJR|UxRTF|Lk[1xsDDucLiMD65NuKh|ryP MWGyOFk6PjF|Nh?=
A549 M{\YdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXy0POKhcA>? Mn7sSG1UV8Li M1r4SWlEPTB;MkSxMlnDqMLzwrCzNU4zO8LizszN MUOyOFk6PjF|Nh?=
MCF7 NV22fJI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTOOFjDqGh? MWPEUXNQyqB? NX\F[GU3UUN3ME24NU4xQcLiwsJCpFE1NjJzwrFOwG0> M33JTlI1QTl4MUO2
HL-60  Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHBe5I{PzMEoHi= MUHJR|UxRTBwMUNihKXPxE1? M1v6e|I1QTl|MEG0
HL-60[R] NULqc|lVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLJb2ZQPzMEoHi= M1jIeGlEPTB;Mz6xNwKBjc7:TR?= NHrKeGkzPDl7M{CxOC=>
MIAPACA NXvrfIp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmi1S2k2OD1zLkOgxtEhOC5yMzFOwG0> M3W0WVI1QTV|OEKx
MCF-7 M1;xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHXS2k2OD1yLkK1JOKyKDBwMTFOwG0> M363UlI1QTV|OEKx
HeLa NXHD[WdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorCS2k2OD1yLk[0JOKyKDBwNDFOwG0> MWiyOFk2Ozh{MR?=
MO59K  MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3mfno4KGR? MkH2TWM2OD1yLkG35qCG|ryP NW[zb2hvOjR7NUO1OlE>
MO59J M2r3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXoV29ZPyCm M4rxS2lEPTB;MD6x5qCG|ryP NFnN[GMzPDl3M{W2NS=>
ME 180 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPUWFM1QMLiaNMg MULJR|UxRThwOdMgxtHDqDBwM,MAie69VQ>? NHfRV4QzPDl3M{CyOy=>
MCF-7 MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfzV|A{PDkEoHlCpC=> Mm\XTWM2OD1{Mz65JOKyKDBwM,MAie69VQ>? NGH6OnkzPDl3M{CyOy=>
HeLa NGDzW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[0POKhcMLi NHW5cFBKSzVyPUSuO|EhyrFiMT605qCG|ryP M{G0eFI1QTV|MEK3
MDA-MB-453 M1fBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;MOFjDqGkEoB?= MYPJR|UxRTF{LkWgxtEhOC56NfMAie69VQ>? NV7tdpAxOjR7NUOwNlc>
MDA-MB-231 NW\CNVduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHHOFjDqGkEoB?= NH\zfYVKSzVyPUK0MlIzKMLzIEKuPVTjiIYQvF2= Mm\zNlQ6PTNyMke=
PC-3 M{HTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUW0POKhcMLi MlPWTWM2OD1zND60JOKyKDNwMkRihKXPxE1? NXW2fHFDOjR7NUOwNlc>
HT-29 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTT[2tmPDkEoHlCpC=> M4nKfWlEPTB;MkGuOFUhyrFiMz64O-KBjc7:TR?= M2Hyd|I1QTV|MEK3
BGC-823 NFmwXplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjM[ot2PDkEoHlCpC=> MlO1TWM2OD12Mz63OEDDuSB3LkGz5qCG|ryP M4PwVVI1Pzl|OEe3
HeLa M4fuTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fjdVQ5yqCqwrC= MnPMTWM2OD1{MEmuPVAhyrFiMUOuOFIh6oDHzszN NEC0c|YzPDd7M{i3Oy=>
A549 NXW2UHViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTMfGpqPDkEoHlCpC=> MV3JR|UxRTF|OT61OEDDuSB5LkC15qCG|ryP MnPjNlQ4QTN6N{e=
HK-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEGzSnQ1QMLiaNMg M1PUVWlEPTB;OT6xO{DDuSBzLkW45qCG|ryP MYKyOFc6Ozh5Nx?=

... Click to View More Cell Line Experimental Data

In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
+ Expand

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
+ Expand
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+30% PEG 300+H2O
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
Synonyms VP-16, VP-16213

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT02432274 Recruiting Tumors|Solid Malignant Tumors|Osteosarcoma|Differentiated Thyroid Cancer (DTC) Eisai Limited|Eisai Inc. December 29, 2014 Phase 1|Phase 2
NCT02385110 Recruiting Leukemia M.D. Anderson Cancer Center September 23, 2015 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03016871 Not yet recruiting CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 2
NCT03041311 Not yet recruiting Small Cell Lung Cancer G1 Therapeutics, Inc. May 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • Answer:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Related Antibodies

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID